BridgeBio Pharma Total Liabilities 2018-2024 | BBIO
BridgeBio Pharma total liabilities from 2018 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
BridgeBio Pharma Annual Total Liabilities
(Millions of US $) |
| 2023 |
$1,889 |
| 2022 |
$1,866 |
| 2021 |
$1,880 |
| 2020 |
$597 |
| 2019 |
$158 |
| 2018 |
$88 |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Total Liabilities
(Millions of US $) |
| 2024-09-30 |
$1,884 |
| 2024-06-30 |
$1,876 |
| 2024-03-31 |
$1,887 |
| 2023-12-31 |
$1,889 |
| 2023-09-30 |
$1,850 |
| 2023-06-30 |
$1,854 |
| 2023-03-31 |
$1,839 |
| 2022-12-31 |
$1,866 |
| 2022-09-30 |
$1,857 |
| 2022-06-30 |
$1,876 |
| 2022-03-31 |
$1,854 |
| 2021-12-31 |
$1,880 |
| 2021-09-30 |
$1,520 |
| 2021-06-30 |
$1,539 |
| 2021-03-31 |
$1,483 |
| 2020-12-31 |
$597 |
| 2020-09-30 |
$572 |
| 2020-06-30 |
$580 |
| 2020-03-31 |
$541 |
| 2019-12-31 |
$158 |
| 2019-09-30 |
$119 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
|
| 2018-09-30 |
$0 |
| 2017-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.953B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
